International Journal of Clinical Case Reports 2024, Vol.14, No.3, 157-166 http://medscipublisher.com/index.php/ijccr 158 current knowledge that need to be addressed to improve patient outcomes. Additionally, this study will highlight the importance of developing standardized treatment protocols and preventive measures to mitigate the global burden of ALRIs in children. 2 Research Progress in ALRIs 2.1 Recent advancements in understanding the pathophysiology of ALRIs Recent studies have significantly advanced our understanding of the pathophysiology of acute lower respiratory infections (ALRIs) in children. Respiratory syncytial virus (RSV) has been identified as a predominant viral pathogen associated with ALRIs, particularly in children with underlying conditions such as congenital heart disease (CHD) and bronchopulmonary dysplasia (BPD). Children with CHD are at a higher risk of severe RSV-ALRI, with increased rates of hospitalization, intensive care unit (ICU) admissions, and mechanical ventilation needs (Chaw et al., 2019a) . Similarly, children with BPD exhibit higher risks of severe RSV-ALRI outcomes, including prolonged hospital stays and increased need for oxygen supplementation and mechanical ventilation (Chaw et al., 2019b). These findings underscore the importance of understanding the specific pathophysiological mechanisms in vulnerable pediatric populations to develop targeted interventions. 2.2 Innovations in diagnostic techniques Innovations in diagnostic techniques have played a crucial role in the early detection and management of ALRIs. The use of multiplex polymerase chain reaction (PCR) has enabled the identification of multiple viral pathogens in children hospitalized with ALRIs, providing a comprehensive understanding of the viral etiology (Hasuwa et al., 2020). Patient-reported outcome measures (PROMs) have been increasingly recommended for capturing meaningful clinical outcomes in pediatric ALRI studies. However, there is a notable lack of validated PROMs for young children, highlighting the need for further development and validation of these tools to improve clinical trial outcomes and patient care (Oakes et al., 2023). Furthermore, the use of non-invasive ventilation (NIV) strategies, such as continuous positive airway pressure (CPAP) and high flow nasal cannula (HFNC), has shown promise in reducing the need for intubation and treatment failure in children with ALRIs, although more research is needed to confirm these benefits (Wang et al., 2021). 2.3 Development of new treatment protocols The development of new treatment protocols for ALRIs has focused on both preventive and therapeutic strategies. Maternal immunization with pneumococcal conjugate vaccines (PCVs) has been proposed as a potential intervention to reduce ALRIs in infants, with ongoing randomized controlled trials (RCTs) evaluating its efficacy (Chang et al., 2022). The need for improved RSV prophylactics and treatments, particularly for children with underlying conditions such as CHD and BPD, has been emphasized (Chaw et al., 2019a; 2019b). The identification of risk factors for poor outcomes and mortality in children with RSV-ALRI, such as prematurity and comorbidities, further supports the development of targeted treatment protocols to mitigate these risks (Shi et al., 2021). Moreover, addressing socio-economic and environmental determinants, such as poverty and indoor air pollution, is crucial for reducing ALRI mortality in low- and middle-income countries (Sonego et al., 2015). 3 Treatment Strategies for ALRIs in Children 3.1 Antiviral therapies Antiviral therapies are crucial in managing acute lower respiratory infections (ALRIs) caused by viral pathogens such as respiratory syncytial virus (RSV). One promising antiviral treatment is ALX-0171, a trivalent Nanobody with antiviral properties against RSV. A double-blind, randomized, placebo-controlled trial assessed the safety and antiviral activity of nebulized ALX-0171 in hospitalized children with RSV lower respiratory tract infection. The study found that ALX-0171 significantly reduced the RSV viral load compared to placebo, although it did not improve clinical outcomes such as time to clinical response or change in global severity score (Chaw et al., 2019b). This suggests that while antiviral therapies can effectively reduce viral load, their impact on clinical outcomes may require further investigation and earlier intervention.
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==